

October 9, 2024

Company Name : Veritas In Silico Inc.
Representative : Shingo NAKAMURA
Representative Director and CEO
Listed on : TSE Growth
Stock Ticker Code : 130A
Contact Person : Hiroaki HAGIWARA
Director and General Manager,
Administration Division
Email: ir@veritasinsilico.com

Liverpool ChiroChem and Veritas In Silico Agree to Form a Strategic Partnership of mRNA-Targeted Drug Discovery and Development

Liverpool ChiroChem Ltd. (Headquarters: Runcorn, Cheshire, United Kingdom; CEO & Founder: Dr Paul Colbon; hereinafter referred to as “LCC”) and Veritas In Silico Inc. (Headquarters: Shinagawa-ku, Tokyo; Representative Director and CEO: Dr Shingo Nakamura; hereinafter referred to as “VIS”) have agreed to form a strategic partnership that combines LCC’s chemistry platform with VIS’ unique biology platform **ibVIS[®]**. This partnership is aiming to generate the first-in-class and best-in-class assets of small molecule against undisclosed mRNA targets.

LCC and VIS had already conducted preliminary screening analysis from July 2024 and, as the results of analysis were positive, both companies have agreed to deepen their joint drug discovery and development business. In the coming days, the necessary contractual and other procedures will be completed.



Photographed at the VIS office in Gotanda, Tokyo: Dr Paul Colbon, CEO & Founder of LCC on the left, and Dr Shingo Nakamura, Representative Director and CEO of VIS on the right.

- Dr Paul Colbon, founder and CEO of LCC comments;

"Innovation lies at the intersection of scientific disciplines. I am delighted that 2 complementary platform technology companies are working together to create new assets. Equally importantly, the cultural fit between the two teams is as strong as the scientific fit, which is why VIS and LCC are able to work so effectively together."

- Dr Shingo Nakamura, Representative Director and CEO of VIS comments;

"I am happy to announce about the business partnership between LCC and VIS. LCC's unconventional technology based on their unique fragment chemistry and VIS's one targeting mRNAs will jointly create new assets from scratch at the fastest pace. This will be beneficial for patients suffering from diseases for which there is no cure."

This agreement will not result in any changes to the earnings forecast for the fiscal year ending December 2024.

In case any matters requiring disclosure arise in the future, it shall be promptly disclosed.

Note: This document has been translated from the Japanese original for reference purposes only.

In the event of any discrepancy between this translated document and the Japanese original, the Japanese original shall prevail.